Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 1,446 shares of the company’s stock in a transaction on Monday, June 11th. The shares were sold at an average price of $285.18, for a total transaction of $412,370.28. Following the completion of the transaction, the executive vice president now owns 9,562 shares of the company’s stock, valued at $2,726,891.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of NASDAQ:ILMN traded up $2.67 on Thursday, reaching $289.91. 24,499 shares of the company’s stock were exchanged, compared to its average volume of 850,143. The stock has a market capitalization of $41.77 billion, a price-to-earnings ratio of 72.54, a price-to-earnings-growth ratio of 3.04 and a beta of 0.88. Illumina, Inc. has a fifty-two week low of $167.98 and a fifty-two week high of $293.15. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.41 and a current ratio of 2.71.

Illumina (NASDAQ:ILMN) last issued its earnings results on Tuesday, April 24th. The life sciences company reported $1.45 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.02 by $0.43. The company had revenue of $782.00 million for the quarter, compared to analysts’ expectations of $744.30 million. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The firm’s revenue was up 30.8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.64 earnings per share. sell-side analysts expect that Illumina, Inc. will post 4.86 EPS for the current fiscal year.

Several brokerages have recently weighed in on ILMN. BidaskClub upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating in a research note on Thursday, April 19th. ValuEngine downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research note on Thursday, April 26th. Morgan Stanley upped their target price on shares of Illumina from $170.00 to $180.00 and gave the company an “underweight” rating in a research note on Wednesday, April 25th. Barclays upped their target price on shares of Illumina from $215.00 to $235.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 25th. Finally, Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $270.00 target price for the company in a research note on Monday, April 16th. One analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have issued a buy rating and two have issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $253.36.

Several large investors have recently modified their holdings of ILMN. SeaCrest Wealth Management LLC acquired a new stake in shares of Illumina during the fourth quarter worth $154,000. Daiwa Securities Group Inc. raised its holdings in shares of Illumina by 4.3% during the fourth quarter. Daiwa Securities Group Inc. now owns 5,543 shares of the life sciences company’s stock worth $1,211,000 after purchasing an additional 229 shares during the period. LS Investment Advisors LLC raised its holdings in shares of Illumina by 12.6% during the fourth quarter. LS Investment Advisors LLC now owns 3,580 shares of the life sciences company’s stock worth $782,000 after purchasing an additional 402 shares during the period. Sigma Planning Corp acquired a new stake in shares of Illumina during the fourth quarter worth $221,000. Finally, Connable Office Inc. acquired a new stake in shares of Illumina during the fourth quarter worth $215,000. 90.87% of the stock is currently owned by institutional investors.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.